Edwards Lifesciences (NYSE:EW) Releases FY 2025 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its FY 2025 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 2.400-2.500 for the period, compared to the consensus estimate of 2.450. The company issued revenue guidance of $5.6 billion-$6.0 billion, compared to the consensus revenue estimate of $5.8 billion. Edwards Lifesciences also updated its Q1 2025 guidance to 0.580-0.640 EPS.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on EW. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price target on the stock. in a research note on Thursday, January 16th. Daiwa America cut Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Royal Bank of Canada raised their price target on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Finally, The Goldman Sachs Group raised their price target on Edwards Lifesciences from $81.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $79.19.

Edwards Lifesciences Stock Performance

EW traded down $0.15 during trading on Tuesday, reaching $70.95. The company’s stock had a trading volume of 3,405,627 shares, compared to its average volume of 4,396,275. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $96.12. The company’s fifty day moving average price is $72.46 and its 200-day moving average price is $69.26. The company has a market capitalization of $41.85 billion, a price-to-earnings ratio of 10.24, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. On average, equities analysts forecast that Edwards Lifesciences will post 2.56 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total transaction of $34,380.00. Following the completion of the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 8,000 shares of company stock worth $547,430. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.